GSK PLC (LSE: GSK)

GSK PLC (LSE: GSK) is an FTSE 100 listed company focused on the research, development, and manufacturing of innovative medicines. The Company’s pipeline is primarily focused on oncology, immuno-inflammation, HIV, and respiratory therapeutic areas.

Q2 FY23 Financial Highlights (Released on 26 July 2023)

• Top-Line Business: The Company’s top-line business improved 4% YoY during Q2 FY23 with around 18% YoY increase in vaccine sales.
• Profitability: GSK’s operating profit grew by around 98% YoY during Q2 FY23 with an adjusted operating margin of 30.2%.
• Interim Dividend: The Company will pay an interim dividend of 14 pence per share on 12 October 2023 with an ex dividend date of 17 August 2023.
• Upgraded Guidance: GSK has expected a growth ranging from 8% to 10% in its turnover during FY23. Earlier the expectation was in the range of 6%-8%. Furthermore, the Adjusted operating profit is expected to grow around 11%-13% YoY during FY23.

Share Price Chart

Markets are trading in a highly volatile zone currently due to certain macroeconomic issues and geopolitical tensions prevailing. Therefore, it is prudent to follow a cautious approach while investing.

GSK PLC (LSE: GSK) was trading at the current market price of GBX 1,400.80 (as of 26 July 2023, 01:10 PM GMT+1)

Note 1: Past performance is not a reliable indicator of future performance.

Note 2: The reference date for all price data, currency, technical indicators, support, and resistance level is 26 July 2023. The reference data in this report has been partly sourced from REFINITIV.

Note 3: ‘Kalkine reports are prepared based on the stock prices captured either from the London Stock Exchange (LSE) and or REFINITIV. Typically, both sources (LSE and or REFINITIV) may reflect stock prices with a delay which could be a lag of 15-20 minutes. There can be no assurance that future results or events will be consistent with the information provided in the report. The information is subject to change without any prior notice.

Note 4: Dividend Yield may vary as per the stock price movement.’

Disclaimer

References to ‘Kalkine’, ‘we’, ‘our’ and ‘us’ refer to Kalkine Limited.

This website is a service of Kalkine Limited. Kalkine Limited is a private limited company, incorporated in England and Wales with registration number 07903332. Kalkine Limited is authorised and regulated by the Financial Conduct Authority under reference number 579414.

The article has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. No advice or information, whether oral or written, obtained by you from Kalkine or through or from the service shall create any warranty not expressly stated. Kalkine does not intend to exclude any liability which it is not permitted to exclude under applicable law or regulation.

Kalkine does not offer financial advice based upon your personal financial situation or goals, and we shall NOT be held liable for any investment or trading losses you may incur by using the opinions expressed in our publications, market updates, news alerts and corporate profiles. Kalkine does not intend to exclude any liability which it is not permitted to exclude under applicable law or regulation. Kalkine’s non-personalised advice does not in any way endorse or recommend individuals, investment products or services for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a professional authorised financial planner and adviser. You should be aware that the value of any investment and the income from it can go down as well as up and you may not get back the amount invested.

Kalkine Media Limited, an affiliate of Kalkine Limited, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.